Modifications to MeCP2, the protein whose dysfunction underlies most cases of Rett syndrome, may help explain the wide range of symptoms seen in people with the condition, a new mouse study suggests. The study found that combining two chemical MeCP2 modifications produced complex behavioral and molecular effects that differed…
News
Only a small percentage of boys with Rett syndrome received treatment with Daybue (trofinetide) in the more than one year after the therapy was approved in the U.S., according to a real-world study of healthcare claims data. Before treatment, boys treated with Daybue had a greater burden of…
Stimulating the vagus nerve — a large nerve that helps control unconscious bodily functions — partly normalized some measures of sound-related brain activity in a rat model of Rett syndrome, a new study reports. Although vagus nerve stimulation, or VNS, improved some measures of sound-related brain activity, including how…
All 10 patients with Rett syndrome treated with Neurogene‘s gene therapy NGN-401 continued to make developmental gains over 2.5 years of follow-up, with no plateau or loss of skills observed, according to long-term data from a Phase 1/2 clinical trial. The data showed that these gains deepened over time…
Daybu (trofinetide), marketed as Daybue and Daybue Stix in the U.S., could become the first treatment for Rett syndrome neurobehavioral issues in the European Union, if the European Commission approves a committee’s recommendation. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive…
All 12 girls and women with Rett syndrome given the gene therapy candidate TSHA-102 in a clinical trial gained or regained at least one developmental milestone within one year, with consistent responses seen across differing ages and disease severity levels, new trial data show. Longer-term follow‑up data from Part…
All 25 participants in the Phase 3 Embolden study have received their doses of NGN-401, Neurogene’s experimental gene therapy for Rett syndrome, surpassing the trial’s initial enrollment target ahead of schedule. “We are pleased to have completed dosing in the Embolden trial of NGN-401 within our original timeline while…
Stimulating the vagus nerve, part of the autonomic nervous system that regulates involuntary functions, paired with sound tones, may support the development of future therapies for communication deficits in Rett syndrome. Researchers found that VNS-tone pairing changed protein levels in the brain’s sound-processing region in a rat model of…
Mutations in the MECP2 gene  — the main cause of Rett syndrome — may disrupt early development by altering how DNA is three-dimensionally organized within chromatin, the complex of DNA and proteins that packages genetic material inside cells, according to a study in China. “This work provides a new…
Abnormally high activity of the MECP2 gene can profoundly disrupt immature brain cells during early development, but appears to have only modest effects in mature nerve cells, according to a new study. The findings may have important implications for the development of gene therapies for Rett syndrome, which is…
Recent Posts
- The surgery for scoliosis that went frighteningly awry
- Consider this item for your special needs child’s back-to-school checklist
- Combined MeCP2 changes may help explain varied Rett symptoms
- Celebrating the tiny triumphs in life with Rett syndrome
- Few boys with Rett received approved treatment, real-world study shows
- A group of Rett syndrome fathers takes my one-word challenge
- Study offers new clues to how Rett syndrome affects sound processing
- Among its cruel talents, Rett syndrome is a thief of joy
- Rett gene therapy drives lasting developmental gains: Long-term data
- The International Rett Syndrome Foundation conference, then and now